Clinical Trial · NCT05955677

Head-to-head Comparison of [68Ga]Ga-PSMA-D5 With [68Ga]Ga-PSMA-11 PET/CT in PCa Diagnosis, Recurrence, and Metastasis

Overview

To prospectively evaluate the radiodrug biodistribution of a novel PET imaging agent \[68Ga\]Ga-PSMA-D5 in different organs of prostate cancer patients and its diagnostic efficacy in the diagnosis, recurrence and metastasis of prostate cancer, and to compare with \[68Ga\]Ga-PSMA-11.

Sponsor

Anhui Provincial Hospital

Phase

Early Phase 1

Contacts

Qiang Xie, MD (CONTACT)

xieqiang1980@ustc.edu.cn

+8613721108043

Qiang Xie (STUDY_CHAIR)

ClinicalTrials.gov

NCT05955677

Drug / Compound

PSMA-11

Isotope(s):

Target(s):

PSMA

Ligand Class: Small Molecules

Chelator: HBED-CC

PSMA-D5

Isotope(s):

Target(s):

PSMA

Ligand Class: Small Molecules

Chelator: DOTA

Eligibility

Inclusion

Willing to undergo surgery or needle biopsy for pathological examination after examination, or confirmed as prostate cancer by histopathology before or after treatment;
simultaneous \[68Ga\]Ga-PSMA-D5 and \[68Ga\]Ga-PSMA-11 examinations within two weeks;
Prostate cancer detected by PSA or imaging examination, or clinically suspected recurrence after standardized treatment;
Complete MRI images and clinical data (such as PSA level, Gleason grade, etc.);

Exclusion

Other circumstances deemed by the investigator to be inappropriate for trial participation.
Patients with liver and kidney dysfunction;
Concurrent malignant tumors;
Previous alcohol allergy;
Patients who cannot cooperate with the examination;